Eidos Therapeutics
Biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease.
Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.
Visit website: https://eidostx.com/
Details last updated 05-Mar-2020
People at Eidos Therapeutics
Eidos Therapeutics News
Undoing Aging 2018: an initiative to remember
Long Long Life - 22-Mar-2018
45 speakers, scientists and entrepreneurs, presented their work. Attended by 350 people from a t...
Read more...